查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951304

性行為感染傳染病診斷市場－全球產業規模、佔有率、趨勢、機會及預測（依產品、應用、技術、檢測地點、地區及競爭格局分類，2021-2031年）

Sexually Transmitted Diseases, Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Technology, By Location Of Testing, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球性行為感染傳染病（STD）診斷市場預計將從 2025 年的 1,030.7 億美元成長到 2031 年的 1,513.3 億美元，複合年成長率為 6.61%。

此細分市場包括專門用於識別引起梅毒、淋病、披衣菌感染等感染疾病的病原體的試劑、儀器和耗材。市場成長的主要驅動力是這些感染疾病在全球日益普遍，以及政府為促進定期篩檢以支持早期療育和有效治療而推出的各項措施。

市場概覽
預測期 2027-2031
市場規模：2025年 1030.7億美元
市場規模：2031年 1513.3億美元
複合年成長率：2026-2031年 6.61%
成長最快的細分市場 設備和服務
最大的市場 北美洲

根據美國性健康協會引用的2025年監測數據，報告的性行為感染總數比十年前的水平高出13%。雖然這種高發病率推動了市場需求，但圍繞檢測的社會污名卻構成了市場發展的一大障礙。這種污名往往阻礙人們獲得必要的診斷服務，從而抑制了市場滲透和普及。

市場促進因素

全球性行為感染傳染病（STD）發生率的不斷上升是市場成長的根本驅動力，因此，健全的檢測基礎設施對於控制感染傳播和預防長期併發症至關重要。細菌性行為感染的捲土重來，尤其是在已開發地區，迫使醫療系統採購大量基於分子和免疫檢測分析的診斷耗材，以應對不斷成長的患者群體。例如，根據英國衛生安全局2025年6月發布的報告，2024年英格蘭早期梅毒診斷病例數將達到9535例，比前一年成長2%。同時，美國疾病管制與預防中心（CDC）2025年的初步數據顯示，在2024年的監測期內，美國披衣菌感染、淋病和梅毒病例總合超過220萬例，證實了診斷需求的持續成長。

同時，消費者對家用和自採檢測套組的日益普及正在改變診斷格局，其方式是分散醫療服務，並繞過臨床污名和預約等障礙。這項轉變得益於監管機構核准了可在非醫療機構環境中提供檢查室級準確度的商業化分子診斷平台。根據美國食品藥物管理局 (FDA) 2025 年 3 月報告，Visby Medical 公司新核准的女性性健康檢測套組在檢驗中對沙眼披衣菌的檢測準確率達到了 97.2%。高性能自檢測套組的廣泛使用鼓勵了年輕族群定期篩檢，這不僅增加了直接面對消費者的製造商的收入，也減輕了性健康診所的營運負擔。

市場挑戰

圍繞性行為感染傳染病的社會污名是全球診斷市場的主要限制因素，因為它阻礙了人們及時接受篩檢。這種源自於害怕被評斷、尷尬和隱私顧慮的心理障礙，使人們極不願前往診所或使用檢測服務。因此，相當一部分高風險族群避免了必要的檢測，這直接減少了臨床環境中診斷試劑、試劑和耗材的消耗，限制了潛在市場規模，並阻礙了製造商的產生收入。

檢測能力不足的後果體現在感染人數估計值與實際診斷率之間的差異。世界衛生組織（世衛組織）預測，到2024年，全球每天新增性行為感染將超過100萬例，但仍有大量病例未被診斷。這些數據表明，儘管檢測平台已經存在，但由於社會擔憂有效地阻礙了患者進入診斷流程，市場無法充分利用不斷上升的感染率。

市場趨勢

多重核酸增幅檢查(NAAT) 的出現，從根本上改變了臨床工作流程，因為它能夠同時檢測單一患者檢體中的多種病原體。這種向症候群檢測的轉變，解決了披衣菌感染和淋病等常見合併感染的問題，而這些感染往往會被單靶點檢測漏診。將檢測整合到批次中，使檢查室能夠在確保全面診斷的同時，加快結果出具速度並降低營運成本，從而促進了其商業性應用。例如，Hologic 公司報告稱，其分子診斷業務在 2024 年 11 月的收入成長了 9.4%，這主要得益於細菌性陰道炎、念珠菌性陰道炎和滴蟲性陰道炎多重檢測套組銷量的成長。

同時，為性行為感染病原體日益嚴重的抗菌素抗藥性威脅，次世代定序在基因組監測領域的應用正在加速。與傳統診斷方法不同，基因測序能夠幫助公共衛生機構識別特定的抗藥性突變並追蹤傳播叢集，尤其是在淋病奈瑟菌。這項能力對於最佳化治療通訊協定至關重要；正如世界衛生組織（世衛組織）2025年11月的一份報告指出，2022年至2024年間，頭孢曲松和頭孢克肟的抗藥性預計將分別上升至5%和11%，因此亟需應對這些抗藥性菌株。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

5. 全球性行為感染傳染病（STD）診斷市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品分類（設備/服務、耗材、軟體）
    • 依用途（HIV 檢測、HSV 檢測、CT/NG 檢測、梅毒檢測、淋病檢測、其他）
    • 依技術分類（免疫檢測、分子診斷、其他）
    • 依檢測地點（檢查室檢測、就地檢驗、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美性行為感染傳染病（STD）診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲性行為感染傳染病（STD）診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區性行為感染傳染病（STD）診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲性行為感染傳染病（STD）診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美性行為感染傳染病（STD）診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球性行為感染傳染病（STD）診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Becton Dickinson and Company
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • bioMerieux SA
  • Abbott Laboratories Inc.
  • Danaher Corporation
  • Qiagen NV
  • Thermo Fisher Scientific Inc.
  • DiaSorin SpA
  • Bio-Rad Laboratories, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23456

The Global Sexually Transmitted Diseases (STD) Diagnostics Market is projected to expand from USD 103.07 Billion in 2025 to USD 151.33 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 6.61%. This sector comprises reagents, instruments, and consumables specifically designed to identify pathogens causing infections such as Syphilis, Gonorrhea, and Chlamydia. The market's growth is primarily driven by the rising global prevalence of these infections and the rollout of government initiatives that encourage routine screening to support early intervention and effective treatment.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 103.07 Billion
Market Size 2031USD 151.33 Billion
CAGR 2026-20316.61%
Fastest Growing SegmentInstruments and Service
Largest MarketNorth America

According to 2025 surveillance data referenced by the American Sexual Health Association, the total number of reported sexually transmitted infections remained 13% higher than levels recorded ten years prior. While this elevated burden fuels demand, the market faces a significant obstacle due to the social stigma surrounding testing. This stigma often discourages individuals from accessing necessary diagnostic services, thereby impeding broader market penetration and adoption.

Market Driver

The escalating global incidence of sexually transmitted infections acts as a fundamental catalyst for market growth, necessitating a robust testing infrastructure to control outbreaks and prevent long-term complications. The resurgence of bacterial infections, especially in developed regions, compels healthcare systems to acquire increased volumes of molecular and immunoassay-based diagnostic consumables to manage the growing patient load. For instance, the UK Health Security Agency's June 2025 report noted that early-stage syphilis diagnoses in England reached 9,535 cases in 2024, a 2% annual increase, while provisional CDC data from 2025 indicated over 2.2 million total cases of chlamydia, gonorrhea, and syphilis in the United States for the 2024 surveillance period, reinforcing the sustained high demand for diagnostics.

Simultaneously, increasing consumer adoption of at-home and self-collection testing kits is reshaping the diagnostic landscape by decentralizing care and bypassing barriers such as clinical stigma and scheduling logistics. This shift is enabled by regulatory approvals of over-the-counter molecular platforms that provide lab-quality accuracy in private settings. As reported by the FDA in March 2025, the newly authorized Visby Medical Women's Sexual Health Test demonstrated 97.2% accuracy for Chlamydia trachomatis during validation. The availability of high-performance self-tests encourages frequent screening among younger demographics, driving revenue for direct-to-consumer manufacturers and alleviating operational pressure on sexual health clinics.

Market Challenge

Social stigma regarding sexually transmitted diseases constitutes a major restraint on the global diagnostics market by discouraging individuals from seeking timely screening. This psychological barrier, rooted in fear of judgment, embarrassment, or privacy concerns, creates a strong reluctance to visit clinics or utilize testing services. Consequently, a substantial portion of the at-risk population avoids necessary testing, which directly reduces the consumption of diagnostic tests, reagents, and consumables in clinical settings, thereby limiting the addressable market size and restricting revenue generation for manufacturers.

The consequence of this testing gap is highlighted by the disparity between infection estimates and actual diagnostic uptake. According to the World Health Organization, in 2024, more than 1 million sexually transmitted infections were acquired daily worldwide, yet a vast number of these cases remained undiagnosed. This data indicates that despite the availability of testing platforms, the market cannot fully capitalize on the rising prevalence of infections because social apprehension effectively blocks patient entry into the diagnostic ecosystem.

Market Trends

The transition toward Multiplex Nucleic Acid Amplification Tests (NAATs) is fundamentally changing clinical workflows by enabling the simultaneous detection of multiple pathogens from a single patient specimen. This shift toward syndromic panel testing addresses high rates of co-infections, such as chlamydia presenting with gonorrhea, which single-target assays often miss. By consolidating testing into one run, laboratories can reduce turnaround times and operational costs while ensuring comprehensive diagnosis, driving commercial adoption. For example, Hologic, Inc. reported a 9.4% increase in molecular diagnostics revenue in November 2024, largely driven by elevated sales of their multiplex assay for bacterial vaginosis, Candida vaginitis, and Trichomonas vaginalis.

Concurrently, the implementation of Next-Generation Sequencing for genomic surveillance is gaining momentum to combat the escalating threat of antimicrobial resistance in sexually transmitted pathogens. Unlike traditional diagnostics, genomic sequencing allows public health entities to identify specific resistance mutations and track transmission clusters, particularly for Neisseria gonorrhoeae. This capability is essential for tailoring treatment protocols, as highlighted by a November 2025 World Health Organization release which noted that resistance to ceftriaxone and cefixime rose to 5% and 11% respectively between 2022 and 2024, necessitating advanced genomic profiling to manage these resistant strains.

Key Market Players

  • Becton Dickinson and Company
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • bioMerieux S.A.
  • Abbott Laboratories Inc.
  • Danaher Corporation
  • Qiagen N.V.
  • Thermo Fisher Scientific Inc.
  • DiaSorin S.p.A
  • Bio-Rad Laboratories, Inc.

Report Scope

In this report, the Global Sexually Transmitted Diseases (STD) Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Sexually Transmitted Diseases (STD) Diagnostics Market, By Product

  • Instruments And Services
  • Consumables
  • Software

Sexually Transmitted Diseases (STD) Diagnostics Market, By Application

  • HIV Testing
  • HSV Testing
  • CT/NG Testing
  • Syphilis Testing
  • Gonorrhea Testing
  • Others

Sexually Transmitted Diseases (STD) Diagnostics Market, By Technology

  • Immunoassay
  • Molecular Diagnostics
  • Other

Sexually Transmitted Diseases (STD) Diagnostics Market, By Location Of Testing

  • Laboratory Testing
  • Point Of Care Testing
  • Others

Sexually Transmitted Diseases (STD) Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Sexually Transmitted Diseases (STD) Diagnostics Market.

Available Customizations:

Global Sexually Transmitted Diseases (STD) Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Sexually Transmitted Diseases (STD) Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Instruments And Services, Consumables, Software)
    • 5.2.2. By Application (HIV Testing, HSV Testing, CT/NG Testing, Syphilis Testing, Gonorrhea Testing, Others)
    • 5.2.3. By Technology (Immunoassay, Molecular Diagnostics, Other)
    • 5.2.4. By Location Of Testing (Laboratory Testing, Point Of Care Testing, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Sexually Transmitted Diseases (STD) Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Technology
    • 6.2.4. By Location Of Testing
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Technology
        • 6.3.1.2.4. By Location Of Testing
    • 6.3.2. Canada Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Technology
        • 6.3.2.2.4. By Location Of Testing
    • 6.3.3. Mexico Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Technology
        • 6.3.3.2.4. By Location Of Testing

7. Europe Sexually Transmitted Diseases (STD) Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Technology
    • 7.2.4. By Location Of Testing
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Technology
        • 7.3.1.2.4. By Location Of Testing
    • 7.3.2. France Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Technology
        • 7.3.2.2.4. By Location Of Testing
    • 7.3.3. United Kingdom Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Technology
        • 7.3.3.2.4. By Location Of Testing
    • 7.3.4. Italy Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Technology
        • 7.3.4.2.4. By Location Of Testing
    • 7.3.5. Spain Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Technology
        • 7.3.5.2.4. By Location Of Testing

8. Asia Pacific Sexually Transmitted Diseases (STD) Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Technology
    • 8.2.4. By Location Of Testing
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Technology
        • 8.3.1.2.4. By Location Of Testing
    • 8.3.2. India Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Technology
        • 8.3.2.2.4. By Location Of Testing
    • 8.3.3. Japan Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Technology
        • 8.3.3.2.4. By Location Of Testing
    • 8.3.4. South Korea Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Technology
        • 8.3.4.2.4. By Location Of Testing
    • 8.3.5. Australia Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Technology
        • 8.3.5.2.4. By Location Of Testing

9. Middle East & Africa Sexually Transmitted Diseases (STD) Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Technology
    • 9.2.4. By Location Of Testing
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Technology
        • 9.3.1.2.4. By Location Of Testing
    • 9.3.2. UAE Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Technology
        • 9.3.2.2.4. By Location Of Testing
    • 9.3.3. South Africa Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Technology
        • 9.3.3.2.4. By Location Of Testing

10. South America Sexually Transmitted Diseases (STD) Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Technology
    • 10.2.4. By Location Of Testing
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Technology
        • 10.3.1.2.4. By Location Of Testing
    • 10.3.2. Colombia Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Technology
        • 10.3.2.2.4. By Location Of Testing
    • 10.3.3. Argentina Sexually Transmitted Diseases (STD) Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Technology
        • 10.3.3.2.4. By Location Of Testing

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Sexually Transmitted Diseases (STD) Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Becton Dickinson and Company
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. F. Hoffmann-La Roche Ltd.
  • 15.3. Hologic, Inc.
  • 15.4. bioMerieux S.A.
  • 15.5. Abbott Laboratories Inc.
  • 15.6. Danaher Corporation
  • 15.7. Qiagen N.V.
  • 15.8. Thermo Fisher Scientific Inc.
  • 15.9. DiaSorin S.p.A
  • 15.10. Bio-Rad Laboratories, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer